Innovative retatrutide, a combined-action medication targeting equally GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Preliminary clinical research have shown substantial losses in body weight and improvements in physiological markers for patients with obesity . Scientists believe this ground-breaking